Clinical Evidence: What STEP Trials Reveal About Wegovy
Wegovy vs Wegovy for weight management: The Licensing Reality
When comparing Wegovy vs Wegovy for weight management, the fundamental distinction lies in their MHRA-approved indications. Wegovy (semaglutide) is specifically licensed for chronic weight management in adults with BMI ≥30, or BMI ≥27 with weight-related comorbidities, alongside adolescents meeting specific criteria. Ozempic, whilst containing the same active ingredient, holds exclusive licensing for type 2 diabetes management and cannot be legally promoted for weight loss purposes in the UK. This licensing difference reflects the distinct clinical trial programmes each medication underwent, with Wegovy's STEP trials specifically designed to evaluate weight management outcomes.
The clinical evidence supporting Wegovy vs Wegovy for weight management demonstrates why regulatory approval matters. Wegovy's development programme included comprehensive weight management studies involving over 4,500 participants across multiple STEP trials, establishing robust safety and efficacy data for weight loss applications. These trials specifically evaluated semaglutide's impact on weight reduction, cardiovascular risk factors, and quality of life measures in patients seeking weight management solutions. Understanding this evidence-based foundation helps explain why healthcare professionals can confidently prescribe Wegovy for weight management whilst maintaining regulatory compliance.
Wegovy vs Ozempic Weight Loss Results: STEP Trial Evidence
Clinical trials provide the most reliable evidence when evaluating Wegovy vs Wegovy for weight management effectiveness. The STEP 1 trial, published by Wilding et al. in NEJM 2021, demonstrated that patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo. STEP 3 extended these findings, showing ~16% weight reduction when Wegovy was combined with intensive behavioural therapy, whilst STEP 5 confirmed sustained weight loss of ~15.2% at two years.
The SELECT cardiovascular outcomes trial added compelling evidence to the Wegovy vs Ozempic weight loss discussion, demonstrating a 20% reduction in major cardiovascular events (HR 0.80) among participants taking semaglutide for weight management. These peer-reviewed studies establish Wegovy's clinical foundation for weight loss, contrasting with Ozempic's diabetes-focused trial programme. EverydayMeds ensures patients receive evidence-based treatment through our comprehensive clinical assessment process, reviewed by qualified prescribers who understand these critical distinctions.
Pricing Transparency: Wegovy vs Ozempic Weight Loss Costs
Understanding the cost implications when choosing Wegovy vs Wegovy for weight management requires clarity about legal prescribing pathways. Wegovy pricing at EverydayMeds starts from £79.99 for the 0.25mg starter dose with code FIRST40, progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to the maintenance dose of 2.4mg at £209.99. Our Intro Duo bundle (0.25mg & 0.5mg) provides the first two months of treatment for £169.99, whilst the Progress Trio (0.5mg, 1mg & 1.7mg) covers months two through four for £369.99.
The financial consideration in Wegovy vs Wegovy for weight management extends beyond unit pricing to treatment legitimacy and safety. Obtaining Wegovy for weight management purposes involves off-label prescribing, potentially limiting insurance coverage and regulatory protections. EverydayMeds' transparent pricing structure for licensed Wegovy treatment includes comprehensive clinical assessment, prescriber review, and next-day cold-chain delivery. Returning customers benefit from code DOSE25, whilst our Ultimate Stability Trio (three 2.4mg pens) provides three months of maintenance treatment for £649.99, ensuring consistent therapeutic levels.
How Wegovy Works: GLP-1 Mechanism Explained
The pharmacological comparison between Wegovy vs Wegovy for weight management centres on their shared GLP-1 receptor agonist mechanism, which mimics the natural incretin hormone GLP-1. Semaglutide binds to GLP-1 receptors in the brain's appetite control centres, particularly the hypothalamus, reducing appetite signals and promoting satiety after smaller meals. This mechanism explains why patients taking Wegovy report feeling fuller sooner and experiencing reduced food cravings, contributing to the sustainable weight loss observed in clinical trials. The medication also slows gastric emptying, prolonging the feeling of fullness and supporting portion control efforts. Understanding this mechanism helps patients appreciate why Wegovy must be combined with dietary modifications and increased physical activity to achieve optimal weight management outcomes.
Assessment and Ordering: Wegovy vs Ozempic Prescription Process
Obtaining legitimate treatment requires understanding the prescription pathway differences between Wegovy vs Wegovy for weight management applications. EverydayMeds streamlines the Wegovy prescription process through our comprehensive 3-minute online clinical assessment, evaluating BMI criteria, medical history, current medications, and treatment goals. Our qualified prescribers review applications within three working days (24 hours with express service), ensuring each patient meets MHRA licensing criteria for weight management treatment. Once approved, prescriptions are dispensed from our GPhC-registered pharmacy (#9012878) and delivered via next-day cold-chain transport, maintaining the medication's temperature-controlled requirements throughout transit. This regulated approach contrasts with potentially problematic off-label Ozempic prescribing, ensuring patients receive appropriate, legally compliant weight management treatment.
Storage and Practical Considerations: Wegovy vs Ozempic Handling
Practical storage requirements remain identical when comparing Wegovy vs Wegovy for weight management, as both contain semaglutide in FlexTouch pen devices. Wegovy requires refrigeration at 2-8°C before first use, but offers superior travel flexibility with six weeks room temperature storage below 30°C once removed from refrigeration, compared to Mounjaro's 21-day limit. The dose escalation schedule progresses systematically: 0.25mg for weeks 1-4, 0.5mg for weeks 5-8, 1mg for weeks 9-12, 1.7mg for weeks 13-16, and 2.4mg maintenance from week 17 onwards. Each pen delivers four doses via the intuitive FlexTouch mechanism, with dose escalation being mandatory to minimise gastrointestinal side effects. Patients cannot skip escalation steps, making bundle purchases particularly convenient for ensuring treatment continuity without repeated ordering.
UK Weight Loss Results: Real-World Wegovy vs Ozempic Outcomes
Real-world evidence supports the clinical trial findings when evaluating Wegovy vs Wegovy for weight management in UK patients. Post-marketing surveillance data indicates that patients following the licensed Wegovy protocol achieve meaningful weight loss outcomes consistent with STEP trial results, particularly when treatment includes specialist weight management support as recommended in NICE TA875. The structured dose escalation and comprehensive prescriber oversight contribute to improved treatment adherence compared to off-label approaches.
Long-term sustainability represents a crucial factor in Wegovy vs Ozempic weight loss comparisons, with STEP 1 extension data showing patients regained approximately two-thirds of lost weight within one year of discontinuation. This evidence reinforces that weight management requires long-term commitment and ongoing treatment, rather than short-term interventions. EverydayMeds supports sustained treatment through convenient bundle options and streamlined repeat prescribing, helping patients maintain therapeutic consistency essential for long-term weight management success.
Making Your Choice: Wegovy vs Ozempic Weight Loss Decision
The decision between Wegovy vs Wegovy for weight management ultimately centres on accessing evidence-based, legally compliant treatment through qualified healthcare providers. EverydayMeds offers both medications where clinically appropriate - Wegovy for licensed weight management and Ozempic for diabetes treatment - with our prescribers helping determine the most suitable option based on individual medical circumstances. Starting your weight management journey begins with our comprehensive clinical assessment, available 24/7 through our secure online platform. New customers benefit from code FIRST40, whilst existing patients use code DOSE25 for continuing treatment. Contact our clinical team today to discuss your weight management goals and begin your evidence-based treatment programme with the UK's most trusted online weight management pharmacy.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
